Idorsia Ltd
SIX:IDIA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
San-Ai Obbli Co Ltd
TSE:8097
|
JP |
|
Vascon Engineers Ltd
NSE:VASCONEQ
|
IN |
|
AIA Group Ltd
HKEX:1299
|
HK |
|
F
|
Fraser & Neave Holdings Bhd
KLSE:F&N
|
MY |
|
H
|
Huaxia Eye Hospital Group Co Ltd
SZSE:301267
|
CN |
|
Logistea AB
STO:LOGI A
|
SE |
|
E
|
Exxaro Resources Ltd
JSE:EXX
|
ZA |
|
Genex Power Ltd
ASX:GNX
|
AU |
|
I
|
Iceland Seafood Internat hf
ICEX:ICESEA
|
IS |
|
NFC Indonesia Tbk PT
IDX:NFCX
|
ID |
|
Loncor Gold Inc
TSX:LN
|
CA |
|
E
|
Electrica Puntilla SA
SGO:PUNTILLA
|
CL |
|
Nisshin OilliO Group Ltd
TSE:2602
|
JP |
|
Daegu Department Store Co Ltd
KRX:006370
|
KR |
|
T
|
TLI Inc
KOSDAQ:062860
|
KR |
|
Clariant Chemicals India Ltd
NSE:CLNINDIA
|
IN |
|
Bank Linth LLB AG
SIX:LINN
|
CH |
|
Medibio Ltd
ASX:MEB
|
AU |
|
EHang Holdings Ltd
NASDAQ:EH
|
CN |
Idorsia Ltd
Research & Development
Idorsia Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Idorsia Ltd
SIX:IDIA
|
Research & Development
-CHf94.2m
|
CAGR 3-Years
37%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Research & Development
-$104m
|
CAGR 3-Years
18%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Research & Development
-$284.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-37%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Research & Development
-CHf105.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Research & Development
-CHf8.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Research & Development
-CHf1.2m
|
CAGR 3-Years
62%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
Glance View
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
See Also
What is Idorsia Ltd's Research & Development?
Research & Development
-94.2m
CHF
Based on the financial report for Dec 31, 2025, Idorsia Ltd's Research & Development amounts to -94.2m CHF.
What is Idorsia Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
24%
Over the last year, the Research & Development growth was 28%. The average annual Research & Development growth rates for Idorsia Ltd have been 37% over the past three years , 24% over the past five years .
